- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04494269
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
November 5, 2020 updated by: HK inno.N Corporation
An Open-label, Multi-center, Single-dose, Parallel-group Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
The main purpose of this study is to compare the pharmacokinetic and safety of tegoprazan following single oral dose in subjects with hepatic impairment versus healthy control.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
[Pharmacokinetic Assessment]
Measurements
- Tegoprazan and desmethyl tegoprazan (M1) in blood and urine
Endpoints
- Primary endpoints: AUClast and Cmax of tegoprazan and M1
- Secondary endpoints: CL/F, t1/2, AUCinf, and fu of tegoprazan; CLrenal and Ae of tegoprazan and M1
[Safety Assessment]
- Adverse events (AEs)
- Clinical laboratory tests
- Vital sign
- Physical examination
- Electrocardiogram (ECG)
Study Type
Interventional
Enrollment (Anticipated)
28
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Incheon, Korea, Republic of
- Recruiting
- Gachon University Gil Medical Center
-
Seongnam-si, Korea, Republic of
- Recruiting
- Cha Bundang Medical Center
-
Seoul, Korea, Republic of
- Recruiting
- Samsung Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
[Healthy Control Group]
Inclusion Criteria:
- Subjects aged 19 to 70(inclusive) years at the time of signing the informed consent form.
- Subjects with a body weight of ≥ 50 kg and ≤ 90 kg at screening.
- Subjects with AST, ALT, and ALP levels of ≤ 1.5 × upper limit of the normal reference range (ULN) with total bilirubin < 2 mg/dL and PT (INR) < 1.7 at screening.
- Subjects who have no chronic disease or any congenital disease within the last 5 years and no pathological symptoms or findings as a result of an internal examination
- Subjects who provide voluntary written informed consent to study participation after being informed of detailed explanation and fully understanding study objectives, procedures and characteristics of the investigational product(IP).
Exclusion Criteria:
- Subjects who show symptoms of acute disease at the time of screening.
- Subjects with any clinically significant disease related to ongoing cardiovascular problem, respiratory system, kidney, endocrine system, hematologic, central nervous system, mental health disorder, or malignant tumor.
- Subjects with history or current evidence of gastrointestinal or hepatobiliary disease which may affect PK evaluation of the IP.
- Subjects with history or current evidence of clinically significant hypersensitivity to drugs containing any ingredient of proton pump inhibitors or potassium-competitive acid blockers and other drugs (such as aspirin and antibiotics).
- Subjects with systolic blood pressure (BP) of < 90 mmHg or > 160 mmHg, or diastolic BP of < 50 mmHg or > 100 mmHg at screening.
- Subjects who have received medication or food which may significantly affect absorption, distribution, metabolism, or elimination of study drug within 7 days prior to scheduled study treatment.
- Subjects who have participated in any other clinical study or bioequivalence study and received investigational agent within 180 days prior to scheduled study treatment.
- Subjects who have donated whole blood within 60 days prior to the scheduled study treatment, or has donated blood components or received transfusion within 30 days prior to scheduled study treatment.
- Subjects who are unable to use a medically acceptable contraceptive method throughout the study.
- Subjects who are determined ineligible for study participation by the investigator for other reasons.
[Subjects with Hepatic Impairment]
Inclusion Criteria:
Subjects with chronic liver disease who meet any of the followings:
- Chronic Hepatitis B;
- Chronic Hepatitis C;
- Alcoholic liver disease;
- Non-alcoholic fatty liver disease; or
- Liver fibrosis and cirrhosis.
- Subjects aged 19 to 70 years (inclusive) at the time of signing the informed consent form.
- Subjects with body weight of ≥ 50 kg and ≤ 90 kg with a BMI of ≥ 18.0 kg/m2 and ≤ 30 kg/m2 at screening.
Subjects who meet any of following criteria:
- AST, ALT, or ALP level > 1.5 × ULN at screening;
- Total bilirubin ≥ 2 mg/dL at screening; or
- PT (INR) ≥ 1.7 at screening.
- Subjects who provide voluntary written informed consent to study participation after being informed of detailed explanation and fully understanding study objectives, procedures and characteristics of the IP.
Exclusion Criteria:
- Subjects who show symptoms of acute disease at the time of screening.
- Subjects with any clinically significant disease related to ongoing cardiovascular problem, respiratory system, kidney, endocrine system, hematologic, central nervous system, mental health disorder, or malignant tumor.
- Subjects with a history or current evidence of gastrointestinal disease which may affect PK evaluation for the IP.
- Subjects who have clinical changes to an estimated level that may affect PK evaluation of the study drug within 30 days prior to the scheduled dosing date.
- Changes in existing medications including dosage regimen within 30 days prior to the scheduled dosing date.
- Subjects with prior history or current evidence of clinically significant hypersensitivity to drugs containing any ingredient of proton pump inhibitors or potassium-competitive acid blockers and other drugs (such as aspirin and antibiotics).
- Systolic BP of < 90 mmHg or > 160 mmHg, or diastolic BP of < 50 mmHg or > 100 mmHg at screening.
- Any concomitant medications or foods which may significantly affect absorption, distribution, metabolism, or elimination of the study drug within 7 days prior to the scheduled dosing date.
- Subjects who have participated in any other clinical study or bioequivalence study and received investigational agent within 180 days prior to scheduled study treatment.
- Subjects who have donated whole blood within 60 days prior to the scheduled dosing date, or have donated blood components or received transfusion within 30 days prior to the scheduled dosing date.
- Subjects who are unable to use medically acceptable contraceptive methods throughout the study.
- Subjects who are determined to be ineligible for study participation by the investigator for other reasons.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Subjects with normal hepatic function
Single dose of Tegoprazan 50mg
|
Oral administration once daily
Other Names:
|
EXPERIMENTAL: Subjects with mild hepatic impairment
Single dose of Tegoprazan 50mg
|
Oral administration once daily
Other Names:
|
EXPERIMENTAL: Subjects with moderate hepatic impairment
Single dose of Tegoprazan 50mg
|
Oral administration once daily
Other Names:
|
EXPERIMENTAL: Subjects with severe hepatic impairment
Single dose of Tegoprazan 50mg
|
Oral administration once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic Assessment
Time Frame: Up to 48 hours
|
AUClast of tegoprazan and M1
|
Up to 48 hours
|
Pharmacokinetic Assessment
Time Frame: Up to 48 hours
|
Cmax of tegoprazan and M1
|
Up to 48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic Assessment
Time Frame: Up to 48 hours
|
CL/F of tegoprazan
|
Up to 48 hours
|
Pharmacokinetic Assessment
Time Frame: Up to 48 hours
|
t½ of tegoprazan
|
Up to 48 hours
|
Pharmacokinetic Assessment
Time Frame: Up to 48 hours
|
AUCinf of tegoprazan
|
Up to 48 hours
|
Pharmacokinetic Assessment
Time Frame: Up to 48 hours
|
fu of tegoprazan
|
Up to 48 hours
|
Pharmacokinetic Assessment
Time Frame: Up to 48 hours
|
CLrenal of tegoprazan and M1
|
Up to 48 hours
|
Pharmacokinetic Assessment
Time Frame: Up to 48 hours
|
Ae of tegoprazan and M1
|
Up to 48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Jung-Ryul Kim, MD, PhD, Samsung Medical Center
- Principal Investigator: Yang-Won Min, MD, PhD, Samsung Medical Center
- Principal Investigator: Dong-Seong Shin, MD, PhD, Gachon University Gil Medical Center
- Principal Investigator: Eon-Hye Kim, MD, PhD, Cha Bundang Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 8, 2020
Primary Completion (ANTICIPATED)
June 1, 2023
Study Completion (ANTICIPATED)
December 1, 2023
Study Registration Dates
First Submitted
July 28, 2020
First Submitted That Met QC Criteria
July 28, 2020
First Posted (ACTUAL)
July 31, 2020
Study Record Updates
Last Update Posted (ACTUAL)
November 9, 2020
Last Update Submitted That Met QC Criteria
November 5, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IN_APA_116
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Tegoprazan 50mg
-
HK inno.N CorporationCompletedHealthyKorea, Republic of
-
HK inno.N CorporationCompletedPharmacodynamics | Healthy Male VolunteersKorea, Republic of
-
HK inno.N CorporationUnknownHealthyKorea, Republic of
-
HK inno.N CorporationCompletedErosive Reflux DiseaseKorea, Republic of
-
Pusan National University HospitalCompletedThe Efficacy of Potassium-competitive Acid Blocker in Patients With Laryngopharyngeal Reflux DiseaseLaryngopharyngeal Reflux DiseaseKorea, Republic of
-
HK inno.N CorporationUnknownPharmacokinetics | Pharmacodynamics | Healthy Male VolunteersKorea, Republic of
-
Shandong UniversityNot yet recruitingHelicobacter Pylori InfectionChina
-
HK inno.N CorporationCompleted
-
HK inno.N CorporationCompletedErosive EsophagitisKorea, Republic of
-
HK inno.N CorporationCompletedHelicobacter Pylori InfectionKorea, Republic of